Eurofins Scientific


Core business accelerates, while COVID-19 revenue subsides but remains robust

28/04/21 -"Eurofins continued its strong showing with 44.3% organic top-line growth in Q1, building on its robust performance in the second half of last year. The share price came under pressure on the back of ..."

Pages
47
Language
English
Published on
28/04/21
You may also be interested by these reports :
27/08/26
The target price is unchanged as we make no material changes to our estimates or valuation. While organic growth is likely to remain subdued in H2 ...

12/08/26
Bilfinger’s Q2 revenue grew by 7% to €1.45bn and EBITA by 4% to €77m, both slightly ahead of expectations, but the underlying picture weakened. The ...

06/08/26
Q2 2026 confirmed solid revenue growth, driven by Adecco GBU’s strong performance across the Americas, Asia Pacific and most EMEA regions. While ...

05/08/26
When we last teased on Rentokil (RTO) (REDUCE; UK) ~16 months ago, our optimism stemmed from on-track Terminix integration. The stock price also ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO